Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.

Background: Atopic dermatitis (AD) significantly impacts both the physical ... 46.2% being moderate, and 21.5% with severe AD. The primary caregivers were mostly first-degree family members, with 62% ...

Wilkins says another Frenchie owner from Forsyth, reached out saying his dog also died from being over heated in Rover’s care ...

JRs tend to be especially vulnerable to a pesky condition known as atopic dermatitis or eczema ... Surgery may be needed in more severe cases. Senses like sight, hearing, and scent can, sadly, also ...

Just like humans, dogs can suffer from seasonal allergies triggered by environmental factors such as pollen, mold, and dust ...

With these trends in view, let’s look at the 7 most undervalued biotech stocks to invest in.

Tralokinumab is approved for the treatment of adults with moderate-to-severe atopic dermatitis in the EU, UK, Canada, United Arab Emirates, and Switzerland. It is also approved for adults in the ...

The National Weather Service is continuing to update its forecast for Friday night's severe weather event in the Tri-State. Here's what meteorologists at the agency's Paducah, Kentucky office are ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

placebo experienced gastrointestinal ulceration events, with an overall incidence of less than 1%. "Many patients with moderate to severe atopic dermatitis struggle with chronic, life-disrupting ...